As Biotechnology businesses, Phio Pharmaceuticals Corp. (NASDAQ:PHIO) and EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT), are affected by contrast. This especially applies to their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Phio Pharmaceuticals Corp.||N/A||79.99||7.36M||-2.54||0.00|
|EyePoint Pharmaceuticals Inc.||5.86M||32.01||89.44M||-1.35||0.00|
Table 1 demonstrates Phio Pharmaceuticals Corp. and EyePoint Pharmaceuticals Inc.’s gross revenue, earnings per share (EPS) and valuation.
Table 2 demonstrates the net margins, return on assets and return on equity of Phio Pharmaceuticals Corp. and EyePoint Pharmaceuticals Inc.
|Net Margins||Return on Equity||Return on Assets|
|Phio Pharmaceuticals Corp.||0.00%||-411.5%||-179.4%|
|EyePoint Pharmaceuticals Inc.||-1,526.28%||-414.6%||-142.9%|
Volatility & Risk
A 1.99 beta indicates that Phio Pharmaceuticals Corp. is 99.00% more volatile compared to Standard & Poor’s 500. In other hand, EyePoint Pharmaceuticals Inc. has beta of 2.02 which is 102.00% more volatile than Standard & Poor’s 500.
1.8 and 1.8 are the respective Current Ratio and a Quick Ratio of Phio Pharmaceuticals Corp. Its rival EyePoint Pharmaceuticals Inc.’s Current and Quick Ratios are 2.6 and 2.6 respectively. EyePoint Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than Phio Pharmaceuticals Corp.
Institutional and Insider Ownership
Institutional investors owned 16.1% of Phio Pharmaceuticals Corp. shares and 62.3% of EyePoint Pharmaceuticals Inc. shares. Insiders owned 3% of Phio Pharmaceuticals Corp. shares. Competitively, insiders own roughly 0.5% of EyePoint Pharmaceuticals Inc.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Phio Pharmaceuticals Corp.||-0.73%||3.84%||22.3%||-75.86%||-86.46%||14.88%|
|EyePoint Pharmaceuticals Inc.||-2.21%||21%||28.64%||25%||150%||40.21%|
For the past year Phio Pharmaceuticals Corp.’s stock price has smaller growth than EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc. beats Phio Pharmaceuticals Corp. on 5 of the 9 factors.
EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis. Its lead product candidate is Durasert, (fluocinolone acetonide intravitreal implant), a micro-insert for the treatment of non-infectious uveitis affecting the posterior segment of the eye. In addition, the company's pre-clinical development program focuses on using its core Durasert platform technology to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. It has license agreements with Bausch and Lomb for Retisert product; a license agreement with Alimera for ocular applications of the ILUVIEN device; and a collaboration agreement with Pfizer for the Durasert device delivering latanoprost. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.